MiR-200c-3p Modulates Cisplatin Resistance in Biliary Tract Cancer by ZEB1-Independent Mechanisms.
ZEB1
biliary tract cancer
chemoresistance
cisplatin resistance
epithelial–mesenchymal transition
miR-200c-3p
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
08 Aug 2021
08 Aug 2021
Historique:
received:
13
07
2021
accepted:
03
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
Biliary tract cancer is a major global health issue in cancer-related mortality. Therapeutic options are limited, and cisplatin-based treatment schedules represent the mainstay of first-line therapeutic strategies. Although the gain of survival by the addition of cisplatin to gemcitabine is moderate, acquired cisplatin resistance frequently leads to treatment failures with mechanisms that are still poorly understood. Epithelial-mesenchymal transition (EMT) is a dynamic process that changes the shape, function, and gene expression pattern of biliary tract cancer cells. In this study, we explored the influence of the EMT-regulating miR-200c-3p on cisplatin sensitivity in biliary tract cancer cells. Using gain of function experiments, we demonstrated that miR-200c-3p regulates epithelial cell markers through the downregulation of the transcription factor ZEB1. MiR-200c-3p upregulation led to a decreased sensitivity against cisplatin, as observed in transient overexpression models as well as in cell lines stably overexpressing miR-200c-3p. The underlying mechanism seems to be independent of miR-200c-3p's influence on
Identifiants
pubmed: 34439151
pii: cancers13163996
doi: 10.3390/cancers13163996
pmc: PMC8392278
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Austrian Science Fund FWF
ID : W 1226
Pays : Austria
Organisme : BioTechMed-Graz
ID : Lab Rotation Program 2020
Organisme : Austrian Science Fund
ID : DK-MCD, W 1226
Organisme : Medizinische Universität Graz
ID : START Grant
Références
In Vitro Cell Dev Biol. 1989 Jun;25(6):503-10
pubmed: 2544546
Int J Oncol. 1997 Jun;10(6):1251-5
pubmed: 21533512
Oncol Rep. 2018 Dec;40(6):3821-3829
pubmed: 30272330
Cell Death Dis. 2019 Jan 22;10(2):55
pubmed: 30670688
Hepatology. 2020 Sep;72(3):982-996
pubmed: 31879968
Curr Med Chem. 2017;24(15):1586-1606
pubmed: 27978798
Oncotarget. 2017 May 16;8(20):33621-33630
pubmed: 28422725
Hum Cell. 2021 Jan;34(1):187-200
pubmed: 33040228
Mol Clin Oncol. 2013 Jan;1(1):3-11
pubmed: 24649114
J Natl Cancer Inst. 2016 May 31;108(10):
pubmed: 27247353
Biopreserv Biobank. 2019 Oct;17(5):444-451
pubmed: 31194576
Clin Cancer Res. 2011 May 1;17(9):3029-38
pubmed: 21248297
Oncotarget. 2015 May 10;6(13):11652-63
pubmed: 25871474
Res Exp Med (Berl). 1988;188(5):367-75
pubmed: 2852388
Tumour Biol. 2016 Aug;37(8):10553-62
pubmed: 26852750
Tohoku J Exp Med. 1995 Sep;177(1):61-71
pubmed: 8693487
Cancer Manag Res. 2014 Apr 25;6:205-16
pubmed: 24812525
Front Mol Biosci. 2020 Mar 19;7:36
pubmed: 32266287
Oncol Lett. 2019 Feb;17(2):1453-1460
pubmed: 30675199
Nat Commun. 2021 Apr 16;12(1):2284
pubmed: 33863904
Int J Mol Sci. 2020 Jun 03;21(11):
pubmed: 32503307
J Mol Med (Berl). 2016 Jun;94(6):629-44
pubmed: 27094812
Int J Mol Sci. 2016 Dec 07;17(12):
pubmed: 27941621
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820942615
pubmed: 33174523
Turk J Urol. 2019 Nov 29;46(1):26-30
pubmed: 31905122
Oncol Lett. 2019 Jul;18(1):145-152
pubmed: 31289483
Int J Clin Exp Pathol. 2019 Oct 01;12(10):3870-3876
pubmed: 31933776
Ann Transl Med. 2019 Apr;7(7):141
pubmed: 31157262
Clin Exp Pharmacol Physiol. 2020 Aug;47(8):1464-1472
pubmed: 32198770
BMC Bioinformatics. 2006 Mar 09;7:123
pubmed: 16526949
Mol Clin Oncol. 2019 Aug;11(2):201-207
pubmed: 31316774
Cell Physiol Biochem. 2015;37(5):1869-80
pubmed: 26584286
J Int Med Res. 2020 May;48(5):300060520918061
pubmed: 32406793
Transplantation. 2004 Feb 15;77(3):446-51
pubmed: 14966424
Hum Cell. 1988 Mar;1(1):95-7
pubmed: 3154020
Cell Mol Life Sci. 2016 Dec;73(24):4643-4660
pubmed: 27460000
Jpn J Clin Oncol. 2018 Aug 1;48(8):703-711
pubmed: 29893894
Biomed Pharmacother. 2020 Apr;124:109863
pubmed: 31986411
Anticancer Drugs. 2019 Mar;30(3):218-224
pubmed: 30431444
Eur J Obstet Gynecol Reprod Biol X. 2019 Apr 06;3:100017
pubmed: 31404211
Tumour Biol. 2016 Oct;37(10):12905-12913
pubmed: 27448297
J Cell Mol Med. 2017 Jan;21(1):177-184
pubmed: 27619971
Pharmacol Res. 2016 Apr;106:27-36
pubmed: 26804248
Tumour Biol. 2016 Feb;37(2):2127-36
pubmed: 26346170
AAPS J. 2018 Jul 9;20(5):82
pubmed: 29987691
Adv Biol Regul. 2015 Jan;57:1-9
pubmed: 25294678
World J Gastroenterol. 2005 Jun 14;11(22):3392-7
pubmed: 15948244
Oncotarget. 2015 Apr 10;6(10):7774-87
pubmed: 25860934
Jpn J Clin Oncol. 2020 Dec 16;50(12):1353-1363
pubmed: 33037430
Oncotarget. 2017 Apr 13;8(31):51190-51199
pubmed: 28881640
Sci Rep. 2017 Mar 03;7:43109
pubmed: 28256505
Cells. 2020 Jan 23;9(2):
pubmed: 31979244
Lancet. 2021 Jan 30;397(10272):428-444
pubmed: 33516341
Oncotarget. 2016 Dec 13;7(50):83060-83070
pubmed: 27825112
Gastroenterol Jpn. 1987 Aug;22(4):474-9
pubmed: 2889643
Biomed Pharmacother. 2019 Feb;110:400-408
pubmed: 30530042
JHEP Rep. 2021 Jan 19;3(2):100226
pubmed: 33665585
Cancer Biomark. 2020;28(3):351-363
pubmed: 32417760
Hum Cell. 2020 Jul;33(3):695-708
pubmed: 32207095
Int J Mol Sci. 2019 Jun 12;20(12):
pubmed: 31212809
J Carcinog. 2015 Feb 23;14:1
pubmed: 25788866
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
Mol Carcinog. 2018 Feb;57(2):295-302
pubmed: 28981169
Cell Death Dis. 2018 Dec 5;9(12):1171
pubmed: 30518916
Acta Biochim Pol. 2019 Dec 28;66(4):509-520
pubmed: 31883362
BMC Cancer. 2018 Oct 23;18(1):1032
pubmed: 30352575